Drugs / Bivalent Moderna
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy2 trials | ||||||
| Phase 3 | NCT05658523 Comparator | Feb 2023 → Oct 2024 overdue | COVID-19 | Murdoch Childrens Research Institute | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05543356 Comparator | May → Jul 2022 | COVID-19 | Murdoch Childrens Research Institute | Withdrawn | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Bivalent Moderna | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05543356 ↗ |
| Known as | mRNA-1273.214 | “Biological/Vaccine: Moderna, mRNA-1273.214 - bivalent The Moderna bivalent vaccine (mRNA-1273.214) encodes the prefusion stabilized S protein of SARS-CoV-2 formulated in...” NCT05543356 ↗ |
| Modality | Messenger RNA (mRNA) | “bivalent mRNA Moderna COVID-19 vaccine” NCT05658523 ↗ |